Innate Pharma has been focused on protecting inventions in United States(US) with three publications in Q4 2023

The United States(US) Patent Office dominates the patent filings and grants with nearly 33% filings and 33% grants. The United States(US), European Patent Office(EPO), Australia(AU), and China(CN) patent Office are among the top ten patent offices where Innate Pharma is filings its patents. Among the top granted patent authorities, Innate Pharma has 33% of its grants in United States(US), 33% in China(CN) and 33% in Spain(ES).

Patents related to rare diseases lead Innate Pharma's portfolio

Innate Pharma has the highest number of patents in rare diseases. For rare diseases, nearly 100% of patents were filed and 100% of patents were granted in Q4 2023.

Breast cancer related patents lead Innate Pharma portfolio followed by cutaneous lupus erythematosus, and solid tumor

Innate Pharma has highest number of patents in breast cancer followed by cutaneous lupus erythematosus, solid tumor, melanoma, and head and neck cancer.

For comprehensive analysis of Innate Pharma's filings and grants, buy the databook here.

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

Be better informed